Synthesis and evaluation of antimicrobial activity of new 1,3,5-triazine derivatives


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Aim. Synthesis of new 1,3,5-triazine derivatives (studied compounds, target compounds) and evaluation of their antimicrobial activity in silico and in vitro. Material and methods. The target compounds were obtained as a result of the reaction of 2,5-disubstituted-4-hydroxy-6H-1,3-oxazin-6-ones and S-methylisothiourea hemisulfate in the presence of an equimolar amount of sodium methylate in a methanol medium. The structure has been proven using modern physico-chemical analysis methods. Computer screening of biological activity was carried out using the PASS program located on the web service and accessible via the Internet. Experimentally, the antimicrobial activity of the compounds was studied in relation to the test culture of the microorganism - Staphylococcus aureus P209. Results. New derivatives of 1,3,5-triazine were synthesized with a yield of 66-72%. The structure of the obtained compounds was proved using 1H and 13C NMR spectroscopy, IR spectroscopy. As a result of screening of biological activity using the PASS program, data on a pronounced antimicrobial effect were obtained. The study of antimicrobial activity in vitro showed that the target compounds have an effect on Staphylococcus aureus P209. Conclusion. New derivatives of 1,3,5-triazine - 2-(methylthio)-4-(4-nitrophenyl)-6-ethyl-1,3,5-triazine, 2-(methylthio)-4-phenyl-6-ethyl-1,3,5-triazine, 2-(methylthio)-4-(4-methylphenyl) were synthesized-6-ethyl-1,3,5-triazine. Their structure has been proved using modern physico-chemical analysis methods. The results of computer prediction made it possible to determine the potential biological activity. Experimental microbiological studies have proved that the studied compounds have antimicrobial activity against Staphylococcus aureus P209.

全文:

受限制的访问

作者简介

E. Kuvaeva

Saint-Petersburg State Chemical and Pharmaceutical University

Email: elena.kuvaeva@pharminnotech.com

Ph.D. (Pharm.), Associate Professor, Department of Organic Chemistry

俄罗斯联邦, Saint-Petersburg, Russia

P. Levshukova

Saint-Petersburg State Chemical and Pharmaceutical University

Email: levshukova.polina@pharminnotech.com

Student

俄罗斯联邦, Saint-Petersburg, Russia

D. Kolesnik

Saint-Petersburg State Chemical and Pharmaceutical University

Email: denis.kolesnik@spcpu.ru

Ph.D. (Pharm.), Assistant, Department of Organic Chemistry

俄罗斯联邦, Saint-Petersburg, Russia

E. Kirillova

Saint-Petersburg State Chemical and Pharmaceutical University

Email: eugenia.kirillova@pharminnotech.com

Ph.D. (Chem.), Associate Professor, Department of Organic Chemistry

俄罗斯联邦, Saint-Petersburg, Russia

I. Yakovlev

Saint-Petersburg State Chemical and Pharmaceutical University

Email: igor.yakovlev@pharminnotech.com

Dr.Sc. (Chem.), Рrofessor, Head of the Department of Organic Chemistry

俄罗斯联邦, Saint-Petersburg, Russia

Yu. Ladutko

Saint-Petersburg State Chemical and Pharmaceutical University

编辑信件的主要联系方式.
Email: yulia.ladutko@pharminnotech.com

Ph.D. (Pharm.), Аssociate Professor, Department of Medicinal Forms Technology

俄罗斯联邦, Saint-Petersburg, Russia

参考

  1. Patel R.V., Kumari P., Rajani D.P., Chikhalia K.H. Synthesis, characterization and pharmacological activities of 2-[4-cyano-(3-trifluoromethyl)phenyl amino)]-4-(4-quinoline/-coumarin-4-yloxy)-6-(fluoropiperazinyl)-s-triazines. Journal of Fluorine Chemistry. 2011; 132: 617-627.
  2. Shah D.R., Modh R.P., Chikhalia K.H. Privileged s-triazines: structure and pharmacological applications. Future Med. Chem. 2014; 6(4): 463-477. doi: 10.4155/fmc.13.212.
  3. McKay G.A., Reddy R., Arhin F., Belley A., Lehoux D., Moeck G., Sarmiento I., Parr T.R., Gros P., Pelletier J., Far A.R. 3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6. Bioorganic & Medicinal Chemistry Letters. 2006; 16: 1286.
  4. Baldaniya B.B., Patel P.K. Synthesis, Antibacterial and Antifungal Activities of s-Triazine Derivatives. Eur. Journal of Chemistry. 2009; 6(3): 673.
  5. PASS Online. Way2Drug: [веб-ресурс]. Москва. URL: www.way2drug.com/PASSOnline (дата обращения 24.01.2021). Режим доступа: для зарегистрир. пользователей. Текст: электронный.
  6. Государственная фармакопея Российской Федерации. МЗ РФ. Изд. XIV. Т. 3. М., 2018; 1187 с.
  7. Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012; 944 с.
  8. Патент 2765005 С1 РФ. Способ получения 2-(метилтио)-4-(4-нитро-фенил)-6-этил-1,3,5-триазина. Д.А. Колесник, Е.В. Куваева, Т.Л. Семакова, О.Ю. Стрелова, И.П. Яковлев, Г.В. Ксенофонтова; заявитель и патентообладатель ФГБОУ ВО СПХФУ Минздрава России. № 2020139481; заявл. 30.11.2020; опубл. 24.01.2022.

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1

下载 (20KB)
3. Fig. 2

下载 (21KB)
4. Fig. 3

下载 (16KB)
5. Fig. 4

下载 (9KB)

版权所有 © Russkiy Vrach Publishing House, 2022
##common.cookie##